Quick Answer
Tyra Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $77.39 million for the year ending 2025.
- Tyra Biosciences, Inc. showed a decrease of -15.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Tyra Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $18.07 million | Q1 2021: $140.64 million | Q2 2021: $135.20 million | Q3 2021: $312.82 million | Q1 2022: $292.50 million | Q2 2022: $275.11 million | Q3 2022: $263.21 million | Q1 2023: $241.70 million | Q2 2023: $232.41 million | Q3 2023: $215.65 million | Q1 2024: $254.37 million | Q2 2024: $99.49 million | Q3 2024: $103.89 million | Q1 2025: $100.72 million | Q2 2025: $98.49 million | Q3 2025: $61.95 million.
- Over the full 6 years of available data (2020 to 2025), Tyra Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 408.3%.
- Historical annual values: Fiscal year 2025: $77.39 million | Fiscal year 2024: $91.97 million | Fiscal year 2023: $58.01 million | Fiscal year 2022: $251.21 million | Fiscal year 2021: $302.18 million | Fiscal year 2020: $15.22 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: